Lawrence D. Wagman, MD, FACS

Lawrence D. Wagman, MD, FACS, executive medical director of St. Joseph&rsquo;s Hospital, discusses the future of precision medicine and genetic testing in the community.

Wagman says that he would like to see a separation between data that might be interesting in the future, from data that will have immediate impact on treatment or access to clinical trials. Real-world application remains of the upmost important to community oncologists who must integrate these protocols into their day-to-day routines.

Community physicians need to be more careful about explaining what genetic risk means to their patients, says Wagman. It is important that the patient understands the difference between a 1% risk and an 80% risk. He adds that he would also like to see more consistency in reporting from genetic testing companies.

Videos

Lawrence D. Wagman, MD, FACS, executive medical director of St. Joseph&rsquo;s Hospital, discusses the future of precision medicine and genetic testing in the community.<br />
&nbsp;

Lawrence D. Wagman, MD, FACS | Authors

Articles

The Future of Precision Medicine and Genetic Testing in the Community